THE DANGERS of giving aspirin or antibiotics to patients on anticoagulant therapy are widely recognised. Aspirin and other salicylates which themselves produce a mild hypoprothromibinaemia are also gastric irritants. Gastrointestinal bleeding may follow the use of these drugs. The possible causes of such bleeding were reviewed by Watson and Pierson (1961) . Antibiotic therapy can affect anticoagulant control by interfering with the source of Vitamin K from the intestinal flora and thus indirectly affecting prothrombin production in the liver. In addition to these there is a growing list of other drugs which potentiate anticoagulant therapy. Attention has recently been drawn to the reduced anticoagulant requirements of certain patients treated with Atromid, a preparation used to reduce serum triglyceride and cholesterol levels (Oliver, Roberts, Hayes, Partridge, Suzman and Bersohn, 1963) . A similar effect on anticoagulant therapy was noted by Winters and Soloff (1962) in a patient in whom hypercholesterolaemia was treated with D-thyroxine.
Other drugs reported to potentiate anticoagulant therapy were reviewed by Hellemans (1962) and include dinitrophenol, chlorpromazine, p-amino salicylic acid, testosterone, alcohol and probenecid. Quinine hydrochloride, chloroquine and hydroxychloroquine have also been reported as having an anticoagulant action (Mandel, 1962) and could therefore be expected to exert a synergistic effect on anticoagulant therapy. Kindermann (1961) reported two cases of spontaneous bleeding after combined therapy with phenindione and phenylbutazone (butazolidin) in the management of superficial thrombophlebitis; and earlier Humble (1953) had reported anomalies in blood clotting in patients on butazolidin. The purpose of this communication is to report a patient on anticoagulant therapy who showed marked prolongation of the prothrombin time and spontaneous bleeding some two weeks after beginning a course of the reliated compound oxyphenylbutazone (Tanderil).
Case Report
The patient, a printer, with known rheumatic heart disease and a history of angina for nine years, was aged 50 years when, in May 1960, he was admitted to hospital with a posterior myocardial infarct. He was discharged from hospital to continue on long term anticoagulant therapy with phenindione.
A year later in May 1961 he developed multiple small spontaneous bruises and a small subconjunctival haemorrhage, during the course of an upper respiratory tract infection with a productive cough.
The Quick one-stage prothrombin time was 3.2 times that of the control plasma (therapeutic range 2.0-2.5). Further slight spontaneous bruising occurred in May POSTGRADUATE MEDICAL JOURNAL 1962. The Thrombotest result at this time was 7.4%, the accepted therapeutic range being 10-15% (Miller, Farrer-Brown and Pether, 1964 This known action of the closely related compound, together with the time relationship between the exhibition of oxyphenylbutazone and the onset of escape from control and bleeding lead us to conclude that, in this case, the oxyphenylbutazone potentiated anticoagulant therapy, presumably by a mechanism similar to that produced by phenylbutazone; it must be admitted, however, that Strobel (1963) found no alteration in one stage prothrombin time, fibrinogen or platelet count after oxyphenylbutazone.
It seemed to us important to draw attention to the possible haemorrhagic hazards of combined therapy with anticoagulants and phenylbutazone or its derivatives. There are, of course, other side effects of phenylbutazone which make such combined therapy a matter for caution. Mauer (1955) reviewed the literature on the toxicity of phenylbutazone and summarised reports from 26 papers covering a total of 3934 patients. In this series he found 415 patients with upper gastrointestinal symptoms with 23 cases of gastrointestinal bleeding and 40 cases of peptic ulcer. Other toxic manifestations included 32 cases of thrombocytopenia, as well as diarrhoea, toxic hepatitis, rashes, blood dyscrasias, water retention and cardiac decompensation. Oxyphenylbutazone is generally accepted as having the same adverse reactions as the parent compound, though possibly giving rise to fewer gastrointestinal disturbances. (Council on Drugs 1963 ).
An annotation in the British Medical Journal (1962) estimated that some 100,000 persons were probably receiving phenylbutazone each week. The widespread use of this drug and related compounds makes it important that the hazards of such therapy should be widely known. It would seem wise for reasons discussed above to avoid using these drugs in the treatment of patients who are already receiving anticoagulants. If, however, in a particular patient, this combination of drugs seems necessary, extremely careful control of anticoagulant therapy is advisable.
Summary
Attention is drawn to the growing list of drugs reported to potentiate anticoagulant therapy.
A case is reported of a patient, well controlled for many months on a constant dose of warfarin sodium, in whom a dramatic fall in prothrombin time followed the administration of Tanderil.
Great caution is advised in undertaking combined therapy with this drug, or its parent compound phenylbutazone, and anticoagulants.
We wish to thank Professor Sir Charles Dodds for his interest and Dr. J. D. N. Nabarro for his permission to publish clinical details of this patient. Also we acknowledge wi,th thanks the great help given by Pharmaceutical Specialities (May and Baker) Ltd. who searched the literature and their personal reports for information on the effect of Stemetil on blood coagulation. We are also grateful to Evans Medical Ltd. and the Geigy Pharmaceutical Co. Ltd. for information supplied; and to those who helped us with problems in translation.
